JP4705782B2 - 肥満の処置のためのプロスタグランジン化合物 - Google Patents

肥満の処置のためのプロスタグランジン化合物 Download PDF

Info

Publication number
JP4705782B2
JP4705782B2 JP2004546433A JP2004546433A JP4705782B2 JP 4705782 B2 JP4705782 B2 JP 4705782B2 JP 2004546433 A JP2004546433 A JP 2004546433A JP 2004546433 A JP2004546433 A JP 2004546433A JP 4705782 B2 JP4705782 B2 JP 4705782B2
Authority
JP
Japan
Prior art keywords
alkyl
prostaglandin
compound
hydroxy
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004546433A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006506381A5 (enExample
JP2006506381A (ja
Inventor
隆司 上野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
Sucampo GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo GmbH filed Critical Sucampo GmbH
Publication of JP2006506381A publication Critical patent/JP2006506381A/ja
Publication of JP2006506381A5 publication Critical patent/JP2006506381A5/ja
Application granted granted Critical
Publication of JP4705782B2 publication Critical patent/JP4705782B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2004546433A 2002-10-23 2003-10-22 肥満の処置のためのプロスタグランジン化合物 Expired - Fee Related JP4705782B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42033602P 2002-10-23 2002-10-23
US60/420,336 2002-10-23
PCT/JP2003/013453 WO2004037268A1 (en) 2002-10-23 2003-10-22 Prostaglandin compounds for the treatment of obesity

Publications (3)

Publication Number Publication Date
JP2006506381A JP2006506381A (ja) 2006-02-23
JP2006506381A5 JP2006506381A5 (enExample) 2006-12-07
JP4705782B2 true JP4705782B2 (ja) 2011-06-22

Family

ID=32176556

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004546433A Expired - Fee Related JP4705782B2 (ja) 2002-10-23 2003-10-22 肥満の処置のためのプロスタグランジン化合物

Country Status (11)

Country Link
US (1) US8114911B2 (enExample)
EP (1) EP1562604B1 (enExample)
JP (1) JP4705782B2 (enExample)
AT (1) ATE539756T1 (enExample)
AU (1) AU2003274735B2 (enExample)
CA (1) CA2502439C (enExample)
DK (1) DK1562604T3 (enExample)
ES (1) ES2379652T3 (enExample)
NZ (1) NZ539582A (enExample)
PT (1) PT1562604E (enExample)
WO (1) WO2004037268A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004030245D1 (de) * 2003-07-03 2011-01-05 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
WO2007111806A2 (en) 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
ES2687494T3 (es) * 2011-01-19 2018-10-25 Topokine Therapeutics, Inc. Métodos y composiciones para reducir la grasa corporal
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
CA2869676C (en) 2012-11-21 2015-06-23 Topokine Therapeutics, Inc. Uses and compositions comprising a thiazolidinedione and oleic acid for locally increasing subcutaneous fat
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
CN110840899A (zh) 2013-04-12 2020-02-28 阿勒根公司 用于减脂的比马前列素、比马前列素类似物、前列腺酰胺和前列腺素的持续释放
NO2753788T3 (enExample) 2013-05-10 2018-06-16
WO2014186504A1 (en) 2013-05-15 2014-11-20 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
US10188661B2 (en) 2014-06-27 2019-01-29 Topokine Therapeutics, Inc. Topical dosage regimen
US11452703B2 (en) 2020-05-21 2022-09-27 Peregrine Ophthalmic PTE LTD. Methods and compositions for reducing adipocyte numbers

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US388919A (en) * 1888-09-04 Benjamin scables
US3888919A (en) * 1971-03-11 1975-06-10 Upjohn Co 11,15 dimethyl pge' 1 'and pgf' 1'
CA1322749C (en) * 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5221763A (en) * 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5317032A (en) * 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
JP2597629B2 (ja) 1988-02-26 1997-04-09 株式会社 上野製薬応用研究所 １３，１４−ジヒドロ−１５−ケトプロスタグランジン類の安定化
NZ226199A (en) 1988-09-15 1991-05-28 Ueno Seiyaku Oyo Kenkyujo Kk 13,14-dihydro-15-keto-pgf derivatives and pharmaceutical compositions
NZ226198A (en) 1988-09-15 1991-05-28 Ueno Seiyaku Oyo Kenkyujo Kk Fervescence (temperature raising) composition comprising 15-keto-pge
JPH085794B2 (ja) * 1989-07-27 1996-01-24 株式会社上野製薬応用研究所 高脂質血症処置・血中脂質成分低下剤
DE69006964T2 (de) * 1989-07-27 1994-06-09 Ueno Seiyaku Oyo Kenkyujo Kk Behandlung von Hyperlipidemia mit 15-keto-Prostaglandin-Verbindungen.
US5234954A (en) * 1989-07-27 1993-08-10 K.K. Ueno Seiyaku Oyo Kenkyujo Treatment of hyperlipidemia with 15-keto-prostaglandin compounds
CA2039420C (en) * 1990-04-04 1996-12-10 Ryuji Ueno Treatment of cataract with 15-keto-prostaglandin compounds
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
US6022897A (en) * 1995-04-25 2000-02-08 The Salk Institute For Biological Studies Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
EP0857718B1 (en) * 1996-06-10 2002-08-14 Sucampo AG Endothelin antagonist
EP1071429B1 (en) * 1998-04-17 2002-01-30 Trustees Of Tufts College Map kinase inhibitors in the treatment of disorders caused by tnf-alpha induced lipolysis
JP2000157260A (ja) 1998-11-26 2000-06-13 Toyobo Co Ltd 初代前駆脂肪細胞の分化誘導方法及びその分化用培地
KR100830061B1 (ko) * 1999-10-15 2008-05-16 수캄포 아게 이환식 화합물 조성물 및 이의 안정화 방법
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
MXPA03010510A (es) * 2001-05-18 2004-03-02 Sucampo Ag Composicion catartica.
MXPA04002006A (es) * 2001-08-31 2004-06-07 Sucampo Ag Analogos de prostagladina como abridor del canal de cloruro.
AR037524A1 (es) * 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
US7732487B2 (en) * 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
MXPA05006981A (es) * 2002-12-27 2005-12-14 Sucampo Ag Derivados de prostaglandinas para el tratamiento de la molestia abdominal.
DE602004030245D1 (de) * 2003-07-03 2011-01-05 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
TWI387454B (zh) * 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
JP5711442B2 (ja) * 2005-04-12 2015-04-30 スキャンポ・アーゲーＳｕｃａｍｐｏ ＡＧ 胃腸障害の処置のためのプロスタグランジン化合物およびプロトンポンプ阻害剤の併用

Also Published As

Publication number Publication date
WO2004037268A1 (en) 2004-05-06
EP1562604A1 (en) 2005-08-17
AU2003274735A1 (en) 2004-05-13
DK1562604T3 (da) 2012-04-02
US20050261373A1 (en) 2005-11-24
CA2502439A1 (en) 2004-05-06
NZ539582A (en) 2007-07-27
AU2003274735B2 (en) 2008-12-04
CA2502439C (en) 2011-11-22
PT1562604E (pt) 2012-04-09
US8114911B2 (en) 2012-02-14
ATE539756T1 (de) 2012-01-15
JP2006506381A (ja) 2006-02-23
EP1562604B1 (en) 2012-01-04
ES2379652T3 (es) 2012-04-30

Similar Documents

Publication Publication Date Title
US20100298424A1 (en) Method for treating abdominal discomfort
JP4332353B2 (ja) １５−ケト−プロスタグランジン類を含む薬物誘発性便秘処置用組成物
AU2002251554A1 (en) Composition for Treating Drug-Induced Constipation
JP2008291033A (ja) １５−ケトプロスタグランジンを含む胆汁分泌促進剤組成物
JP4705782B2 (ja) 肥満の処置のためのプロスタグランジン化合物
JP5294559B2 (ja) クロライドチャンネルオープナーとしてプロスタグランジンアナログを含む腸溶性組成物
JP5427029B2 (ja) 消化管の重炭酸分泌を促進するための方法および組成物
US6956056B2 (en) Method for providing a cathartic effect
JP2004529177A (ja) 高眼圧症および緑内障の処置方法
JP4091132B2 (ja) 門脈圧亢進抑制剤
JP2004521960A (ja) 高眼圧症および緑内障の処置のための方法および組成物
JP2005519978A (ja) 高眼圧症および緑内障の処置方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061017

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061017

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100601

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100831

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101201

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110215

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110314

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees